Company Overview and News
ADTRAN, Inc. (ADTN - Free Report) recently announced that it is leading an initiative within the Broadband Forum to leverage application-level traffic generation for advanced broadband testing. The initiative will benefit service providers, vendors and testing labs by allowing them to manage the increasingly complex subscriber traffic on the network. It is likely to have far-reaching positive effects on the whole industry.
Ericsson (ERIC - Free Report) Consumer & IndustryLab recently unveiled its latest Insight Report — the Zero touch customer experience. The report is aimed at exploring the future of customer interactions with mobile service providers. The report gathered insights based on both quantitative and qualitative research methods. Quantitative data was collected from seven markets — Brazil, China, Germany, South Korea, Sweden, the U.
Verizon Communications Inc. (VZ - Free Report) is in talks with Sacramento to lease the 5,000 square-foot property near City Hall as a data center, which once housed the city’s information technology department in 2014. The property has been lying vacant since then. City spokesperson Marycon Young feels that the space, located in Suite 190 of the City Hall garage on I Street, between 10th and 11th streets, is already equipped with the necessary infrastructure, eliminating the need for a large-scale upgrade.
When BlackBerry's litigation against Avaya for patent infringement was settled on February 20, 2018, the terms were not disclosed.
Millennials — population with birth years ranging from 1980-2000 — are slowly turning out to be the backbone of the U.S. economy, outpacing baby boomers in 2015 and reflecting over one quarter of the nation’s population. By 2019, millennials will be America’s largest population cohort, as projected by the United States Census Bureau.
The PowerShares QQQ Trust, Series 1 (ETF) (NASDAQ:QQQ) — an ETF (Exchange Traded Fund) that tracks 100 of the largest U.S. and international non-financial stocks listed on the NASDAQ Index — has been a mixed bag this year.
CenturyLink, Inc. (CTL - Free Report) is scheduled to report first-quarter 2018 financial results after the closing bell on May 9. The company is likely to report higher consolidated revenues on the back of healthy growth dynamics. Whether this could result into an earnings beat for the quarter remains to be seen. Factors at Play During the first quarter, CenturyLink received approval from the U.S.
Here at Zacks, we don’t generally classify stocks as “cheap” or “expensive”, and rather than looking at the stock’s face value, we have a system that puts an emphasis on earnings estimate revisions to find stocks that will hopefully be winners for investors.
The portfolio continues to be very concentrated with the top five positions accounting for ~44% of the 13F holdings.
Investors are always looking for stocks that are poised to beat at earnings season and EOG Resources, Inc. (EOG - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
Investors are always looking for stocks that are poised to beat at earnings season and DowDuPont Inc. (DWDP - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
Investors are always looking for stocks that are poised to beat at earnings season and Church & Dwight Co., Inc. (CHD - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because Church & Dwight is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.
The Aerospace group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has The Boeing Company (BA - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Wichita, KS-based Spirit AeroSystems Holdings, Inc. (SPR - Free Report) is a manufacturer and supplier of large aircraft structures. Commercial aircraft manufacturer, Boeing, has to depend on Spirit AeroSystems for bare fuselages of its 737 and 787 airplanes. In addition, Spirit AeroSystems contributes to other commercial and defense programs.
AC Immune SA (ACIU - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for ACIU broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.
2017-10-26 - Asif
BlackBerry is securing a connected world, delivering innovative solutions across the entire mobile ecosystem and beyond. The Company secures the world’s most sensitive data across all endpoints – from cars to smartphones – making the mobile-first enterprise vision a reality. Founded in 1984 and based in Waterloo, Ontario, the Company operates offices in North America, Europe, Middle East and Africa, Asia Pacific and Latin America. The Company’s common shares are listed on the NASDAQ Global Select Market (“NASDAQ”) (NASDAQ: BBRY) and the Toronto Stock Exchange (“TSX”) (TSX: BB), and its Debentures are listed on the TSX (TSX: BB.DB.U). The Mobile Communications Industry Improvements in wireless network infrastructure and the rapid proliferation of mobile devices and applications in recent years are transforming the way that enterprises and individuals communicate and collaborate. In the enterprise, the mobile platform is becoming the primary computing platform and users now ex...
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
as of ET